DHR · US market
Danaher Corp
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$148.86bnFinancials dated 26 June 2026Price dated 1 October 2026
Core valuation
Calculation inputs
- Trailing earnings
- US$4.00bn
- Latest-quarter run-rate earnings
- US$3.48bn
- Latest fiscal-year earnings
- US$3.61bn
- Trailing revenue
- US$25.11bn
- Latest-quarter run-rate revenue
- US$25.06bn
- Latest fiscal-year revenue
- US$24.57bn
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- FSMEX · Fidelity Select Medical Technology and Devices Portfolio15.09% weight · Holdings dated 31 May 2026
- EAALX · Eaton Vance-Atlanta Capital Focused Growth Fund Class A8.91% weight · Holdings dated 30 June 2026
- WVAIX · Weitz Large Cap Equity Fund - Institutional Class8.22% weight · Holdings dated 30 June 2026
- CSIEX · Calvert Equity Fund Class A4.69% weight · Holdings dated 30 June 2026
- CILGX · Clarkston Fund Institutional Class4.53% weight · Holdings dated 30 June 2026
- MVAL · VanEck Morningstar Wide Moat Value ETF4.42% weight · Holdings dated 30 June 2026
- BMED · iShares Health Innovation Active ETF3.65% weight · Holdings dated 21 August 2026
- FMED · Fidelity Disruptive Medicine ETF3.42% weight · Holdings dated 31 May 2026
- LZUSX · Lazard US Equity Focus Portfolio Institutional Shares3.18% weight · Holdings dated 30 June 2026
- PBLAX · Principal Blue Chip Fund Class A3.08% weight · Holdings dated 31 May 2026
Sources and limitations
Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 26 June 2026. Informational research, not investment advice.